Entrada Therapeutics (TRDA) Change in Acquisitions & Divestments (2022 - 2026)

Entrada Therapeutics' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $38.9 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 54.79% year-over-year to $38.9 million; the TTM figure through Mar 2026 stood at $212.4 million (down 43.38% YoY), while the FY2025 annual figure was $259.5 million, down 37.19% from the prior year.
• Change in Acquisitions & Divestments was $38.9 million for Q1 2026 at Entrada Therapeutics, down from $47.4 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $123.9 million in Q1 2024 to a low of $1.7 million in Q1 2022.
• Historically, Change in Acquisitions & Divestments has averaged $62.5 million across 5 years, with a median of $63.0 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Change in Acquisitions & Divestments surged 3575.61% in 2023, then tumbled 60.01% in 2025.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $19.5 million in 2022, then surged by 456.62% to $108.5 million in 2023, then gained by 9.17% to $118.5 million in 2024, then sank by 60.01% to $47.4 million in 2025, then dropped by 18.0% to $38.9 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $38.9 million (Q1 2026), $47.4 million (Q4 2025), and $75.5 million (Q3 2025), per Business Quant data.